Literature DB >> 2783321

Bacterial lipopolysaccharide and inflammatory mediators augment IL-6 secretion by human endothelial cells.

F R Jirik1, T J Podor, T Hirano, T Kishimoto, D J Loskutoff, D A Carson, M Lotz.   

Abstract

The interaction between human endothelial cells and leukocytes during immunologic and inflammatory responses is in part mediated through the release of soluble mediators. We report that cultured human umbilical vein endothelial cells secrete IL-6 when stimulated with LPS. This effect was inhibited by polymyxin-B. The monokines IL-1 and TNF-alpha were also potent inducers of IL-6, whereas lymphotoxin was only effective at much higher concentrations. Endothelial cell supernatant IL-6 was active as hybridoma-plasmacytoma growth factor and as B-cell stimulating factor. Endothelial IL-6 activity was neutralized by a specific anti-IL-6 antibody and by immunoprecipitation it was shown to be identical in size to human fibroblast-derived IL-6. As IL-6 is possibly an important regulator of host defense responses, production of this cytokine by endothelial cells may contribute to the pathogenesis of various inflammatory and immunologic diseases.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2783321

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  101 in total

Review 1.  Interleukin-6 and insulin sensitivity: friend or foe?

Authors:  A L Carey; M A Febbraio
Journal:  Diabetologia       Date:  2004-07-07       Impact factor: 10.122

2.  Elevated interleukin-6 levels in sera of patients with fulminant hepatitis.

Authors:  Y Shiratori; H Moriwaki; Y Kawashima; K Ando; F Asano; M Shimazaki; H Ohnishi; Y Muto; M Okuno
Journal:  Gastroenterol Jpn       Date:  1991-04

Review 3.  Interleukin-1, immune activation pathways, and different mechanisms in osteoarthritis and rheumatoid arthritis.

Authors:  B Kirkham
Journal:  Ann Rheum Dis       Date:  1991-06       Impact factor: 19.103

Review 4.  Interleukin-6 and the acute phase response.

Authors:  P C Heinrich; J V Castell; T Andus
Journal:  Biochem J       Date:  1990-02-01       Impact factor: 3.857

5.  Dose-dependent increase in plasma interleukin-6 after recombinant tumour necrosis factor infusion in humans.

Authors:  N Sheron; J N Lau; J Hofmann; R Williams; G J Alexander
Journal:  Clin Exp Immunol       Date:  1990-12       Impact factor: 4.330

Review 6.  The endothelium: its role in scleroderma.

Authors:  J D Pearson
Journal:  Ann Rheum Dis       Date:  1991-11       Impact factor: 19.103

7.  Comparative studies on inflammatory reactions induced by non-immunological and immunological stimuli in an air pouch and in a carboxymethyl cellulose (CMC)-induced inflammatory pouch.

Authors:  M Isaji; J Naito
Journal:  Int J Exp Pathol       Date:  1992-04       Impact factor: 1.925

8.  Endotoxin-mediated endothelial cell injury and activation: role of soluble CD14.

Authors:  M Arditi; J Zhou; R Dorio; G W Rong; S M Goyert; K S Kim
Journal:  Infect Immun       Date:  1993-08       Impact factor: 3.441

9.  The use of angiostatic steroids to inhibit cartilage destruction in an in vivo model of granuloma-mediated cartilage degradation.

Authors:  P R Colville-Nash; M el-Ghazaly; D A Willoughby
Journal:  Agents Actions       Date:  1993-01

10.  Hemostatic abnormalities and the severity of illness in patients at the onset of clinically defined sepsis. Possible indication of the degree of endothelial cell activation?

Authors:  B Leithäuser; F R Matthias; U Nicolai; R Voss
Journal:  Intensive Care Med       Date:  1996-07       Impact factor: 17.440

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.